RxDoctor Payments Data

Oana Patrascu, MD

Family Medicine · Sugar Grove, ILNPI 1245304989

Payments from drug & device makers

$1,708in general payments, 2019–2025

Across 42 payments — averaging $40.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$241
  • Kerecis Limited$240
  • Smith+Nephew$214
  • Integra Lifesciences Corporation$173
  • Organogenesis Inc.$122
  • Tactile Systems Technology Inc$97
  • plus $621 from 17 others

What the payments were for

  • Food & beverage$1,708100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,708 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$62,029
Medicare patients
161
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide32$37,688
RybelsusSemaglutide12$24,749
OzempicSemaglutide23$20,331
JardianceEmpagliflozin15$14,989
LinzessLinaclotide12$8,260
Breo ElliptaFluticasone/Vilanterol12$4,595
Arnuity ElliptaFluticasone Furoate12$4,331
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen73$2,836
Bupropion Hcl SrBupropion Hcl35$1,620
Gabapentin67$1,463
Atorvastatin Calcium185$1,364
Metoprolol Succinate61$1,216
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,093
Omeprazole78$1,023
Pantoprazole Sodium40$892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$29$45,07935 claims
GSKBreo Ellipta, Arnuity Ellipta$19$8,92624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Sugar Grove

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →